Your browser is no longer supported. Please, upgrade your browser.
CYTK Cytokinetics, Incorporated daily Stock Chart
CYTK [NASD]
Cytokinetics, Incorporated
Index- P/E- EPS (ttm)-2.37 Insider Own0.80% Shs Outstand70.50M Perf Week-3.73%
Market Cap1.13B Forward P/E- EPS next Y-2.08 Insider Trans-41.61% Shs Float69.97M Perf Month-23.55%
Income-140.40M PEG- EPS next Q-0.30 Inst Own85.20% Short Float12.55% Perf Quarter-31.92%
Sales18.70M P/S60.41 EPS this Y-8.20% Inst Trans0.44% Short Ratio5.65 Perf Half Y7.75%
Book/sh-1.31 P/B- EPS next Y-1.00% ROA-58.10% Target Price- Perf Year43.13%
Cash/sh3.07 P/C5.30 EPS next 5Y15.00% ROE363.30% 52W Range7.72 - 30.14 Perf YTD53.25%
Dividend- P/FCF- EPS past 5Y-38.80% ROI-83.50% 52W High-46.05% Beta1.30
Dividend %- Quick Ratio9.60 Sales past 5Y-10.60% Gross Margin- 52W Low110.49% ATR1.91
Employees156 Current Ratio9.60 Sales Q/Q-49.30% Oper. Margin- RSI (14)36.37 Volatility5.65% 8.38%
OptionableYes Debt/Eq- EPS Q/Q-22.80% Profit Margin- Rel Volume0.50 Prev Close16.56
ShortableYes LT Debt/Eq- EarningsAug 06 AMC Payout- Avg Volume1.55M Price16.26
Recom2.00 SMA20-21.53% SMA50-26.46% SMA200-12.32% Volume774,870 Change-1.81%
Jul-10-20Initiated Raymond James Strong Buy $39
May-05-20Initiated Mizuho Buy $31
Apr-09-20Upgrade Morgan Stanley Equal-Weight → Overweight $25
Sep-21-18Initiated Cantor Fitzgerald Overweight
Sep-10-18Resumed Morgan Stanley Equal-Weight $10
Nov-22-17Reiterated Morgan Stanley Overweight $25 → $17
Nov-22-17Downgrade Needham Strong Buy → Buy $22 → $12
Nov-21-17Reiterated H.C. Wainwright Buy $26 → $17
Jul-31-17Initiated Morgan Stanley Overweight $24
Mar-08-17Initiated Rodman & Renshaw Buy $25
Feb-06-17Upgrade Needham Buy → Strong Buy $17 → $22
Dec-16-16Initiated Cantor Fitzgerald Overweight $21
Jul-28-16Reiterated Needham Buy $15 → $17
Nov-10-15Reiterated FBR Capital Outperform $14 → $24
Nov-09-15Reiterated ROTH Capital Buy $18 → $22
Jul-24-15Reiterated MLV & Co Buy $9 → $14
Dec-31-14Reiterated ROTH Capital Buy $13 → $18
Nov-04-14Upgrade MLV & Co Hold → Buy $9
Apr-28-14Reiterated Needham Buy $25 → $15
Apr-25-14Downgrade MLV & Co Buy → Hold $26 → $5
Oct-13-20 03:24PM  
Oct-09-20 12:46PM  
Oct-08-20 04:13PM  
04:11PM  
10:14AM  
08:30AM  
08:30AM  
Oct-05-20 04:26PM  
04:00PM  
08:48AM  
07:30AM  
Oct-02-20 07:30AM  
Sep-28-20 05:25PM  
Sep-25-20 08:56AM  
Sep-24-20 04:00PM  
07:30AM  
Sep-23-20 07:30AM  
Sep-17-20 07:30AM  
Sep-02-20 04:00PM  
Aug-26-20 07:30AM  
Aug-18-20 07:30AM  
Aug-06-20 04:00PM  
Jul-30-20 12:33PM  
Jul-24-20 08:36AM  
Jul-23-20 04:00PM  
Jul-21-20 04:00PM  
04:00PM  
Jul-20-20 06:39PM  
Jul-16-20 11:32PM  
08:31AM  
Jul-15-20 04:00PM  
07:30AM  
Jul-14-20 07:30AM  
Jul-13-20 07:30AM  
Jul-10-20 10:10AM  
Jul-01-20 04:00PM  
Jun-30-20 11:45AM  
Jun-16-20 09:48PM  
Jun-08-20 04:00PM  
Jun-04-20 11:35AM  
May-27-20 07:30AM  
May-11-20 12:21PM  
May-08-20 08:30AM  
08:30AM  
May-07-20 04:00PM  
04:00PM  
May-06-20 04:00PM  
May-05-20 11:46AM  
May-04-20 05:59PM  
07:58AM  
Apr-30-20 08:33AM  
Apr-29-20 12:34PM  
Apr-22-20 04:00PM  
Apr-14-20 07:30AM  
Apr-08-20 04:00PM  
Apr-01-20 07:32AM  
Mar-30-20 01:35PM  
07:30AM  
Mar-20-20 04:00PM  
Mar-04-20 07:30AM  
Mar-03-20 05:15PM  
04:00PM  
07:30AM  
Feb-28-20 07:30AM  
Feb-26-20 08:30AM  
08:30AM  
Feb-25-20 12:30PM  
Feb-20-20 07:30AM  
Feb-18-20 04:00PM  
Feb-13-20 12:31PM  
Feb-12-20 10:55AM  
Feb-06-20 04:30AM  
Jan-30-20 06:59AM  
Jan-22-20 07:30AM  
Jan-17-20 09:26AM  
Jan-13-20 07:30AM  
Jan-10-20 08:10PM  
Jan-06-20 07:30AM  
Jan-03-20 05:43PM  
Dec-18-19 07:30AM  
Dec-10-19 10:45AM  
Dec-09-19 10:03AM  
Dec-05-19 07:30AM  
Nov-27-19 04:00PM  
09:45AM  
Nov-26-19 04:00PM  
Nov-18-19 09:00AM  
09:00AM  
Nov-11-19 12:14PM  
09:00AM  
Nov-08-19 07:30AM  
Nov-06-19 04:05PM  
Nov-05-19 07:30AM  
Nov-01-19 11:08AM  
Oct-31-19 05:15PM  
04:00PM  
Oct-24-19 04:00PM  
Oct-17-19 10:30AM  
Oct-04-19 07:30AM  
07:30AM  
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274, a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; and AMG 594, a novel cardiac troponin activator that is in Phase I clinical trial. The company has strategic alliances with Amgen Inc. and Astellas Pharma Inc. Cytokinetics, Incorporated was founded in 1997 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blum Robert IPresident & CEOOct 13Option Exercise6.005,00030,000309,868Oct 14 04:53 PM
Blum Robert IPresident & CEOOct 13Sale15.945,00079,686304,868Oct 14 04:53 PM
Malik Fady IbrahamEVP Research & DevelopmentOct 08Sale17.451,25821,952152,182Oct 08 05:08 PM
COSTA SANTO JDirectorOct 05Option Exercise9.4515,000141,75015,000Oct 05 05:53 PM
HENDERSON JOHN TDirectorOct 05Option Exercise12.963,00038,8802,399Oct 05 09:03 PM
Jaw ChingSVP Finance & CFOOct 05Option Exercise10.0327,500275,70088,300Oct 05 08:23 PM
Kaye Edward M. MDDirectorOct 05Option Exercise7.6120,000152,20020,000Oct 05 08:38 PM
SMITH SANDFORD DDirectorOct 05Option Exercise7.375,93643,7485,936Oct 05 09:11 PM
PARSHALL B LYNNEDirectorOct 05Option Exercise7.2350,311363,89820,000Oct 06 04:58 PM
SMITH SANDFORD DDirectorOct 05Sale30.005,936178,0800Oct 05 09:11 PM
HENDERSON JOHN TDirectorOct 05Sale29.003,00087,000899Oct 05 09:03 PM
PARSHALL B LYNNEDirectorOct 05Sale30.0050,3111,509,3300Oct 06 04:58 PM
Jaw ChingSVP Finance & CFOOct 05Sale30.0027,500825,00073,300Oct 05 08:23 PM
COSTA SANTO JDirectorOct 05Sale30.0015,000450,0000Oct 05 05:53 PM
Kaye Edward M. MDDirectorOct 05Sale30.0020,000600,0000Oct 05 08:38 PM
Blum Robert IPresident & CEOOct 02Option Exercise6.005,00030,000309,868Oct 02 05:48 PM
Blum Robert IPresident & CEOOct 02Sale22.535,000112,646304,868Oct 02 05:48 PM
Blum Robert IPresident & CEOSep 21Option Exercise6.005,00030,000309,868Sep 21 05:16 PM
Blum Robert IPresident & CEOSep 21Sale20.975,000104,835304,868Sep 21 05:16 PM
Blum Robert IPresident & CEOSep 11Option Exercise6.005,00030,000309,868Sep 11 05:05 PM
Blum Robert IPresident & CEOSep 11Sale22.955,000114,736304,868Sep 11 05:05 PM
Malik Fady IbrahamEVP Research & DevelopmentSep 10Sale22.8599522,736153,440Sep 11 04:37 PM
Blum Robert IPresident & CEOSep 04Option Exercise6.005,00030,000309,868Sep 04 05:29 PM
Blum Robert IPresident & CEOSep 04Sale22.375,000111,855304,868Sep 04 05:29 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselAug 21Option Exercise7.0310,00070,30040,000Aug 21 05:34 PM
Jaw ChingSVP Finance & CFOAug 21Option Exercise7.5425,000188,40088,300Aug 21 05:41 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselAug 21Sale25.0010,000250,00030,000Aug 21 05:34 PM
Jaw ChingSVP Finance & CFOAug 21Sale25.0025,000625,00073,300Aug 21 05:41 PM
Blum Robert IPresident & CEOAug 18Option Exercise6.005,00030,000309,868Aug 20 04:27 PM
Blum Robert IPresident & CEOAug 18Sale23.485,000117,422304,868Aug 20 04:27 PM
Malik Fady IbrahamEVP Research & DevelopmentAug 13Sale21.8559913,088154,435Aug 14 05:16 PM
Blum Robert IPresident & CEOAug 05Option Exercise6.005,00030,000309,868Aug 07 04:39 PM
Blum Robert IPresident & CEOAug 05Sale22.125,000110,621304,868Aug 07 04:39 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselJul 29Option Exercise7.0310,00070,30040,000Jul 30 07:57 PM
SCHLOSSBERG MARK ASVP - Legal & General CounselJul 29Sale23.0710,000230,72830,000Jul 30 07:57 PM
Blum Robert IPresident & CEOJul 28Option Exercise6.005,00030,000309,868Jul 30 07:56 PM
Blum Robert IPresident & CEOJul 28Sale23.775,000118,829304,868Jul 30 07:56 PM
Blum Robert IPresident & CEOJul 16Option Exercise6.005,00030,000309,868Jul 17 05:15 PM
Blum Robert IPresident & CEOJul 16Sale27.365,000136,806304,868Jul 17 05:15 PM
SMITH SANDFORD DDirectorJul 15Option Exercise6.216,66741,4026,667Jul 17 05:14 PM
SMITH SANDFORD DDirectorJul 15Sale29.006,667193,3430Jul 17 05:14 PM
SMITH SANDFORD DDirectorJul 10Option Exercise6.216,66741,4026,667Jul 13 05:34 PM
SMITH SANDFORD DDirectorJul 10Sale28.006,667186,6760Jul 13 05:34 PM
Malik Fady IbrahamEVP Research & DevelopmentJul 09Sale26.961,58742,786155,034Jul 10 08:09 PM
SMITH SANDFORD DDirectorJul 08Option Exercise6.211,4348,9051,434Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 08Sale27.001,43438,7180Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 07Option Exercise6.4911,74276,2386,510Jul 09 05:37 PM
SMITH SANDFORD DDirectorJul 07Sale26.4511,742310,5240Jul 09 05:37 PM
Blum Robert IPresident & CEOJul 06Option Exercise6.005,00030,000309,868Jul 08 05:08 PM
Blum Robert IPresident & CEOJul 06Sale24.855,000124,255304,868Jul 08 05:08 PM
Blum Robert IPresident & CEOJun 24Option Exercise6.075,00030,354308,689Jun 26 04:41 PM
Blum Robert IPresident & CEOJun 24Sale23.865,000119,309304,868Jun 26 04:41 PM
COSTA SANTO JDirectorJun 22Option Exercise7.6120,000152,20020,000Jun 24 05:40 PM
PARSHALL B LYNNEDirectorJun 22Option Exercise5.3416,51088,14710,000Jun 23 05:00 PM
SMITH SANDFORD DDirectorJun 22Option Exercise4.4410,00044,4005,000Jun 22 05:43 PM
PARSHALL B LYNNEDirectorJun 22Sale25.0016,510412,7500Jun 23 05:00 PM
SMITH SANDFORD DDirectorJun 22Sale24.5010,000245,0000Jun 22 05:43 PM
COSTA SANTO JDirectorJun 22Sale25.0020,000500,0000Jun 24 05:40 PM
SMITH SANDFORD DDirectorJun 17Option Exercise6.806,90746,9944,166Jun 17 06:07 PM
SMITH SANDFORD DDirectorJun 17Sale23.006,907158,8610Jun 17 06:07 PM
SMITH SANDFORD DDirectorJun 15Option Exercise6.306,66641,9966,666Jun 15 05:57 PM
SMITH SANDFORD DDirectorJun 15Sale22.006,666146,6520Jun 15 05:57 PM
SMITH SANDFORD DDirectorJun 12Option Exercise4.4215,04566,48010,879Jun 12 06:31 PM
SMITH SANDFORD DDirectorJun 12Sale20.8615,045313,9070Jun 12 06:31 PM
Blum Robert IPresident & CEOJun 11Option Exercise6.305,00031,500309,868Jun 12 06:32 PM
Blum Robert IPresident & CEOJun 11Sale21.475,000107,354304,868Jun 12 06:32 PM
Blum Robert IPresident & CEOMay 29Option Exercise6.305,00031,500308,633May 29 07:45 PM
Blum Robert IPresident & CEOMay 29Sale20.105,000100,503303,633May 29 07:45 PM
HENDERSON JOHN TDirectorMay 19Option Exercise16.863,33356,1943,583May 20 05:04 PM
GAGE L PATRICKDirectorMay 18Option Exercise16.863,33356,19423,333May 20 05:04 PM
Blum Robert IPresident & CEOMay 18Option Exercise6.304,18926,391307,822May 18 07:37 PM
Blum Robert IPresident & CEOMay 18Sale22.155,000110,732303,633May 18 07:37 PM
COSTA SANTO JDirectorMay 11Option Exercise8.4929,999254,58720,000May 12 04:22 PM
COSTA SANTO JDirectorMay 11Sale19.8229,999594,6870May 12 04:22 PM
COSTA SANTO JDirectorMay 05Option Exercise6.128,33250,9924,166May 06 06:39 PM
COSTA SANTO JDirectorMay 05Sale17.008,332141,6440May 06 06:39 PM
Blum Robert IPresident & CEOMay 01Sale14.345,00071,678304,444May 01 07:06 PM
WIERENGA WENDALLDirectorApr 28Option Exercise10.249,999102,3906,666Apr 29 06:25 PM
WIERENGA WENDALLDirectorApr 28Sale16.009,999159,9840Apr 29 06:25 PM
GAGE L PATRICKDirectorMar 06Sale14.828,000118,59220,000Mar 20 03:21 PM
BVF PARTNERS L P/IL10% OwnerFeb 13Sale15.791,072,03016,923,923424,419Feb 18 06:00 PM
Blum Robert IPresident & CEOJan 15Sale12.964,95064,159224,107Jan 16 04:53 PM
Blum Robert IPresident & CEODec 16Sale10.226,00061,326229,057Dec 17 04:24 PM
BVF PARTNERS L P/IL10% OwnerDec 11Buy9.52118,4131,126,7003,617,776Dec 12 07:49 PM
BVF PARTNERS L P/IL10% OwnerDec 10Buy9.40223,6592,102,3953,557,673Dec 12 07:49 PM
Malik Fady IbrahamEVP Research & DevelopmentDec 05Sale9.801,50014,700121,350Dec 06 04:42 PM
HENDERSON JOHN TDirectorNov 19Buy8.576,00051,4276,250Jan 02 02:22 PM
Blum Robert IPresident & CEONov 15Sale8.086,00048,508235,057Nov 18 04:12 PM
Malik Fady IbrahamEVP Research & DevelopmentNov 07Sale9.981,50014,970122,850Nov 08 05:08 PM